Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke.

Dong-Yi ChenYan-Rong LiChun-Tai MaoChi-Nan TsengI-Chang HsiehMing-Jui HungPao-Hsien ChuChao-Hung WangMing-Shien WenWen-Jin CherngTien-Hsing Chen

Published in: Journal of diabetes investigation (2019)

Among patients with type 2 diabetes mellitus after a recent acute coronary syndrome or acute ischemic stroke, treatment with vildagliptin was not associated with increased risks of CV death, non-fatal myocardial infarction, non-fatal stroke and hospitalization for HF.

Keyphrases

acute ischemic stroke
acute coronary syndrome
percutaneous coronary intervention
antiplatelet therapy
atrial fibrillation
heart failure
human health
coronary artery disease
climate change
risk assessment
brain injury
subarachnoid hemorrhage